# PeptideScanner evidence objects: Cibinetide

Every published version of the records placed with Cibinetide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/cibinetide.json. Selected public evidence only; not medical advice.

- Objects: 4
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct02039687-cibinetide-v1"></a>

## ClinicalTrials.gov record NCT02039687

> PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.

- Evidence object: `story:clinicaltrials-gov-nct02039687-cibinetide:v1`
- Evidence domain: Clinical trials
- Date in source: 2017-04-18
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct02039687-cibinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#clinicaltrials-gov-nct02039687-cibinetide-v1
- Content SHA-256: `65b5847a30288ff143f4dac88b633c552523dbb59035f7c708eb082133bad555`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT02039687 ([`ctg-observation-nct02039687-2017-04-18-f051734c1a3a`](#source-ctg-observation-nct02039687-2017-04-18-f051734c1a3a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide. ([`ctg-observation-nct02039687-2017-04-18-f051734c1a3a`](#source-ctg-observation-nct02039687-2017-04-18-f051734c1a3a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide. ([`ctg-observation-nct02039687-2017-04-18-f051734c1a3a`](#source-ctg-observation-nct02039687-2017-04-18-f051734c1a3a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct02039687-2017-04-18-f051734c1a3a`](#source-ctg-observation-nct02039687-2017-04-18-f051734c1a3a))

### Sources

<a id="source-ctg-observation-nct02039687-2017-04-18-f051734c1a3a"></a>
- **ClinicalTrials.gov record NCT02039687 · retained source version 2017-04-18:f051734c1a3abb348d6258300b66222aba53985becbd09790375934e2a0f9212** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT02039687) (`ctg-observation-nct02039687-2017-04-18-f051734c1a3a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT02039687." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#clinicaltrials-gov-nct02039687-cibinetide-v1 SHA-256: 65b5847a30288ff143f4dac88b633c552523dbb59035f7c708eb082133bad555.

---

<a id="pubmed-pmid-24555851-cibinetide-v1"></a>

## ARA 290 for treatment of small fiber neuropathy in sarcoidosis.

> PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-24555851-cibinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-05-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-24555851-cibinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-24555851-cibinetide-v1
- Content SHA-256: `8410da16d1d505d0a70519b4ba5831b5344d62ab23a59b07539ed88fd864e476`

### Claims and source pins

#### Headline

ARA 290 for treatment of small fiber neuropathy in sarcoidosis. ([`pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e`](#source-pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e))

#### Summary

PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e`](#source-pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e))

#### Paragraph 1

PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e`](#source-pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e`](#source-pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e))

### Sources

<a id="source-pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e"></a>
- **ARA 290 for treatment of small fiber neuropathy in sarcoidosis. · retained source version 1:2018-05-25:current:e32881dcc16e5980e786773d722b98520e964b664c96603c96378c7f042def26** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/24555851/) (`pubmed-observation-pmid-24555851-2018-05-25-e32881dcc16e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ARA 290 for treatment of small fiber neuropathy in sarcoidosis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-24555851-cibinetide-v1 SHA-256: 8410da16d1d505d0a70519b4ba5831b5344d62ab23a59b07539ed88fd864e476.

---

<a id="pubmed-pmid-26774587-cibinetide-v1"></a>

## ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.

> PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-26774587-cibinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2018-05-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-26774587-cibinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-26774587-cibinetide-v1
- Content SHA-256: `ce0dba8db058137c1e4f1f9cb3c0bc622f836fcd63a8c56052c29c00b545d83a`

### Claims and source pins

#### Headline

ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. ([`pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1`](#source-pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1))

#### Summary

PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1`](#source-pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1))

#### Paragraph 1

PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1`](#source-pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1`](#source-pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1))

### Sources

<a id="source-pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1"></a>
- **ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. · retained source version 1:2018-05-25:current:6ccef3c0cfb1a3feb594dac968dad647706a98b96e2e93ad17eb253839062898** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/26774587/) (`pubmed-observation-pmid-26774587-2018-05-25-6ccef3c0cfb1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-26774587-cibinetide-v1 SHA-256: ce0dba8db058137c1e4f1f9cb3c0bc622f836fcd63a8c56052c29c00b545d83a.

---

<a id="pubmed-pmid-32674280-cibinetide-v1"></a>

## A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

> PubMed lists PMID 32674280 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2020-07-14 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32674280-cibinetide:v1`
- Evidence domain: Literature metadata
- Date in source: 2020-09-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32674280-cibinetide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-32674280-cibinetide-v1
- Content SHA-256: `55779b55e20a708055f254d658c2b4e05d152abc7e8d372686a8b491f3493644`

### Claims and source pins

#### Headline

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. ([`pubmed-observation-pmid-32674280-2020-09-28-119290be0a92`](#source-pubmed-observation-pmid-32674280-2020-09-28-119290be0a92))

#### Summary

PubMed lists PMID 32674280 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2020-07-14 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32674280-2020-09-28-119290be0a92`](#source-pubmed-observation-pmid-32674280-2020-09-28-119290be0a92))

#### Paragraph 1

PubMed lists PMID 32674280 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2020-07-14 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32674280-2020-09-28-119290be0a92`](#source-pubmed-observation-pmid-32674280-2020-09-28-119290be0a92))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32674280-2020-09-28-119290be0a92`](#source-pubmed-observation-pmid-32674280-2020-09-28-119290be0a92))

### Sources

<a id="source-pubmed-observation-pmid-32674280-2020-09-28-119290be0a92"></a>
- **A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema. · retained source version 1:2020-09-28:current:119290be0a9227da4e13a6d6e7b17e6b9c7f0db5a220dcd0b910f78571665d5c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32674280/) (`pubmed-observation-pmid-32674280-2020-09-28-119290be0a92`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/cibinetide.json#pubmed-pmid-32674280-cibinetide-v1 SHA-256: 55779b55e20a708055f254d658c2b4e05d152abc7e8d372686a8b491f3493644.

